Microsoft will buy Nuance at $56 per share, representing a 23% premium to Nuance’s closing price on Friday, April 9, 2021. The all-cash transaction is valued at $19.7 billion, inclusive of Nuance’s debt, according to a news release.

Nuance develops conversational AI and cloud-based ambient clinical intelligence for healthcare providers, including the Dragon Ambient eXperience, Dragon Medical One and PowerScribe One for radiology reporting. The company’s platforms work with core healthcare systems, including longstanding relationships with Electronic Health Records (EHRs).

According to the release, Nuance’s platforms are currently used by more than 55% of physicians and 75% of radiologists in the U.S., while they are also used in 77% of U.S. hospitals.

Microsoft said it accelerated its efforts to offer industry-specific cloud platforms, including the Microsoft Cloud for Healthcare, which it introduced last year. The acquisition of Nuance adds to this effort, with the companies building upon an existing partnership established in 2019.

By augmenting the Microsoft Cloud for Healthcare platform with Nuance’s offerings, Microsoft expects to better empower providers with ambient clinical intelligence and other cloud services. The company expects the acquisition to double its total addressable market in the healthcare provider space, bringing the value of the market to nearly $500 billion.

“Nuance provides the AI layer at the healthcare point of delivery and is a pioneer in the real-world application of enterprise AI,” Microsoft CEO Satya Nadella said in the release. “AI is technology’s most important priority, and healthcare is its most urgent application. Together, with our partner ecosystem, we will put advanced AI solutions into the hands of professionals everywhere to drive better decision-making and create more meaningful connections, as we accelerate growth of Microsoft Cloud for Healthcare and Nuance.”

Mark Benjamin will remain Nuance’s CEO and report to Microsoft EVP of cloud & AI, Scott Guthrie. The boards of both companies unanimously approved the deal, which is expected to close by the end of the calendar year, subject to approval by Nuance’s shareholders.

Upon closing, Microsoft expects Nuance’s financials to be reported as part of its intelligent cloud business segment. Microsoft anticipates that the acquisition will be minimally dilutive in 2022 and accretive in 2023 to non-GAAP earnings per share.

“Over the past three years, Nuance has streamlined its portfolio to focus on the healthcare and enterprise AI segments, where there has been accelerated demand for advanced conversational AI and ambient solutions,” Benjamin said. “To seize this opportunity, we need the right platform to bring focus and global scale to our customers and partners to enable more personal, affordable and effective connections to people and care.

“The path forward is clearly with Microsoft — who brings intelligent cloud-based services at scale and who shares our passion for the ways technology can make a difference. At the same time, this combination offers a critical opportunity to deliver meaningful and certain value to our shareholders who have driven and supported us on this journey.”

Strive Health, the national leader in value-based kidney care, announced a strategic partnership with NextGate, the global leader in healthcare enterprise identification, to support Strive’s whole-patient solution for kidney disease populations with accurate, consistent patient identification.

Utilizing NextGate’s market-leading Enterprise Master Patient Index (EMPI) on Amazon Web Services (AWS) to unify and match the right data to the right individual, Strive’s clinical team of Kidney Heroes™ will have access to comprehensive, reliable high-quality data and analysis of its thousands of chronic kidney disease (CKD) and end stage kidney disease (ESKD) patients.

Healthcare providers and payors rely on Strive Health’s comprehensive kidney care model of predictive analytics and high-touch care teams to slow disease progression, reduce hospitalizations, engage patients, and improve quality of life. The addition of cloud-based patient identification technology from NextGate will support Strive with a complete and accurate view of patient data across the continuum to effectively identify gaps in care, avoid acute events, and ensure the right interventions at the right time. The EMPI will also impact Strive’s ability to effectively track its 15,000 kidney patients across six states for population health analytics and quality reporting under value-based care arrangements.

“Strive’s mission is to provide the best tech-enabled, high-touch care for chronic and end stage kidney disease patients. Partnering with NextGate, a trusted industry leader, is crucial to elevating our technology to provide quality whole-person care for patients,” says Sarah Morgan, Data Engineering Lead at Strive Health. “We went through a lengthy vendor review process and were thrilled by the options and value-add that NextGate offers.”

Kidney care in the U.S. has historically been fragmented, and patients have not always experienced the well-orchestrated and personalized care they deserve. Today, CKD affects an estimated 37 million Americans and approximately 90% don’t know they have it. The partnership between NextGate and Strive will serve to deliver a fully connected and de-duplicated kidney care data experience that promotes care quality and operational efficiency, while supporting patients throughout every step of the kidney care journey.

“Consistently connecting the right data to the right individual is a critical requirement in today’s digitized healthcare environment to positively influence outcomes and the patient experience,” said Andy Aroditis, CEO of NextGate. “We applaud Strive Health for prioritizing patient identification as the basis for data integrity and personalized care delivery.”

Strive Health, the national leader in value-based kidney care, today announced a strategic partnership with NextGate, the global leader in healthcare enterprise identification, to support Strive’s whole-patient solution for kidney disease populations with accurate, consistent patient identification.

Utilizing NextGate’s market-leading Enterprise Master Patient Index (EMPI) on Amazon Web Services (AWS) to unify and match the right data to the right individual, Strive’s clinical team of Kidney Heroes™ will have access to comprehensive, reliable high-quality data and analysis of its thousands of chronic kidney disease (CKD) and end stage kidney disease (ESKD) patients.

Healthcare providers and payors rely on Strive Health’s comprehensive kidney care model of predictive analytics and high-touch care teams to slow disease progression, reduce hospitalizations, engage patients, and improve quality of life. The addition of cloud-based patient identification technology from NextGate will support Strive with a complete and accurate view of patient data across the continuum to effectively identify gaps in care, avoid acute events, and ensure the right interventions at the right time. The EMPI will also impact Strive’s ability to effectively track its 15,000 kidney patients across six states for population health analytics and quality reporting under value-based care arrangements.

“Strive’s mission is to provide the best tech-enabled, high-touch care for chronic and end stage kidney disease patients. Partnering with NextGate, a trusted industry leader, is crucial to elevating our technology to provide quality whole-person care for patients,” says Sarah Morgan, Data Engineering Lead at Strive Health. “We went through a lengthy vendor review process and were thrilled by the options and value-add that NextGate offers.”

Kidney care in the U.S. has historically been fragmented, and patients have not always experienced the well-orchestrated and personalized care they deserve. Today, CKD affects an estimated 37 million Americans and approximately 90% don’t know they have it. The partnership between NextGate and Strive will serve to deliver a fully connected and de-duplicated kidney care data experience that promotes care quality and operational efficiency, while supporting patients throughout every step of the kidney care journey.

“Consistently connecting the right data to the right individual is a critical requirement in today’s digitized healthcare environment to positively influence outcomes and the patient experience,” said Andy Aroditis, CEO of NextGate. “We applaud Strive Health for prioritizing patient identification as the basis for data integrity and personalized care delivery.”

Abbott announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – for patients with high bleeding risk (HBR). The approval follows recent results from two studies that demonstrated both one-month or three-month DAPT followed by aspirin monotherapy is safe in HBR patients and is intended to improve patient outcomes and provide physicians more options to treat their patients. XIENCE is the most widely used stent worldwide and is the only stent to have evidence and data for both one-month and three-months DAPT followed by two different types of blood-thinning medication in HBR patients.

Patients who receive stents are typically on DAPT regimens (aspirin and antiplatelet drugs known as P2Y12 inhibitors to prevent blood clots) for six to 12 months to support vessel healing and prevent clotting from blocking the stented vessel. However, HBR patients can experience side effects such as bleeding during prolonged courses of DAPT. Abbott’s XIENCE 28 and XIENCE 901 studies show that DAPT can be safely discontinued early – as short as 28 days – with no increased risk in patient adverse events, further confirming the industry-leading safety profile of the XIENCE stent.

“The results of the studies examining the XIENCE stent in high bleeding risk patients with shorter durations of dual anti-platelet therapy were highly consistent – with no increase in cardiac events and significant reduction in severe bleeding. To see such consistency is important for physicians seeking the best possible outcome for our patients,” says Marco Valgimigli, M.D., Ph.D., deputy chief of CardioCentro Ticino, Lugano, Switzerland and professor of cardiology at the University of the Italian Switzerland (USI).

The XIENCE 28 and XIENCE 90 clinical trials enrolled more than 3,600 participants from Europe, the Americas and Asia. The studies monitored two different DAPT durations – one-month and three-months – in exclusively HBR patients. The results are consistent and conclusive: patients who receive the XIENCE stent with shorter DAPT durations do not have an increase in cardiac events and showed a reduction in severe bleeding, proving short DAPT strategies with the XIENCE stent are safe in HBR patients.

“In patients with high bleeding risk, the XIENCE stent has proven that it can ensure patient safety without compromising efficacy when duration of blood-thinning medications is shortened,” says Nick West, M.D., chief medical officer and divisional vice president of global medical affairs at Abbott’s vascular business. “These findings build on the unrivalled volume of research confirming the XIENCE stent’s leading performance across a range of patient and clinical situations.”

For years, the global interventional cardiology community has focused on research and innovation to support shorter DAPT treatments for patients requiring stents but who may be at a higher risk of bleeding. Abbott has conducted the clinical research needed to evaluate the safety of the XIENCE stent in patients using a shorter DAPT duration. These investments in clinical research have built a body of evidence that has impacted what has long been the standard of care for patients after coronary stenting. The XIENCE stent is used in life-saving treatments that can help prevent or treat heart attacks and has now consistently been proven safe with short DAPT strategies for HBR patients. Abbott is also seeking an indication for HBR for the XIENCE stent in the U.S.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Komodo Health and Klick Health announced a strategic partnership making Klick the premier life sciences marketing agency to leverage Komodo’s Healthcare Map™ – a real-world data and analytics platform. The alliance will give Klick clients access to the industry’s most complete view of anonymized patient encounters and enable demonstrably more insightful and targeted healthcare marketing programs.

With Klick as the leading commercialization partner for a growing number of life sciences companies, today’s announcement reinforces the value Klick offers its clients to enhance health outcomes across a wide array of therapeutic areas. The news also bolsters Komodo’s continued market growth as a foundational enterprise technology platform, designed to connect the dots between individual patient journeys and large-scale health outcomes.

“We are thrilled to work with Klick to extend our unique capabilities in support of their life sciences clients,” said Komodo Co-Founder and CEO Arif Nathoo, MD. “There are a lot of synergies between our entrepreneurial organizations, and together we can help marketers navigate today’s complex healthcare landscape using our advanced analytics and intelligence tools.”

Klick Co-Founder and Chairman Leerom Segal said, “Our strategic partnership with Komodo is a real game-changer, giving our clients the best healthcare intelligence for optimizing program and campaign design, delivery, and performance. It’s also a great example of how we keep leaning into our digital roots and adopting the latest data-driven approaches to give our clients a competitive edge and make a positive difference in health.”

Komodo’s Healthcare Map™ integrates disparate sources of patient-level data to provide the industry’s most precise view of the U.S. healthcare system. The platform provides the critical insights necessary to optimize commercial strategy, analyze competitive market share, and identify the key decision makers essential for driving treatment decisions. It is helping the world’s leading life sciences companies, health plans, and patient advocacy groups close gaps in care, address unmet patient needs, improve engagement, and ultimately help drive novel therapies into the market.

About Klick Health
Klick Health is the world’s largest independent commercialization partner for life sciences. For over two decades, Klick has been laser-focused on developing, launching, and supporting life sciences brands to maximize their full market potential. Klick was named Large Agency of the Year for 2020 by Medical Marketing + Media (MM+M), marking its ninth Agency of the Year industry award in nine years.

About Klick Group
The Klick Group of companies – Klick Health (including Klick Katalyst), Klick Media Group, Klick Applied Sciences (including Klick Labs), Klick Consulting, Klick Ventures, and Sensei Labs – is an ecosystem of brilliant talent collectively working to maximize their people and clients’ full potential. Established in 1997, Klick has teams in New York, Philadelphia, Toronto, and across North America. Klick has consistently been named a Best Managed Company and Great Place to Work. In 2020, the company was recognized with 14 Best Workplace awards, including Best Workplaces for Women, Best Workplaces for Inclusion, Employee-Recommended Workplaces, Most Admired Corporate Cultures, and FORTUNE’s Best Places to Work in New York.

About Komodo Health
Komodo Health believes that smarter, more innovative use of data and analytics is essential for reducing disease burden. We apply artificial intelligence and other advanced data science techniques to our first-of-its-kind Healthcare Map™, which tracks the unique patient journeys of over 325 million patients. We empower a multitude of healthcare stakeholders – life sciences companies, healthcare payers and providers, patient advocacy groups, and others – to create a more cost-effective, value-driven healthcare system.

Hologic, Inc., a global leader in women’s health, announced that it has signed a definitive agreement to acquire Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, for an enterprise value of approximately $795 million. This includes a cash payment of approximately $714 million (€600 million) for Mobidiag’s equity, and net debt of approximately $81 million.

“Acquiring Mobidiag will further strengthen our international and diagnostics businesses by enabling us to expand into the large, fast-growing acute care adjacency with a near-patient testing solution that offers ease of use, multiplex capability and rapid turnaround time,” said Jan Verstreken, group president, international at Hologic. “We believe that Mobidiag has developed a differentiated platform that addresses many of the historical challenges of multiplexed point-of-care molecular testing.”

“We are very excited to join Hologic’s diagnostic business,” said Tuomas Tenkanen, Mobidiag’s chief executive officer. “Hologic’s commercial expertise and scale will drive broader market adoption of our products, and their established U.S. regulatory and market development capabilities will accelerate the introduction of our products and maximize their potential in the United States.”

Mobidiag develops and markets PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections. The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours.

The Novodiag platform combines real-time PCR and microarray capabilities to provide high-level multiplexing. Multiplexing enables multiple pathogens to be identified in a single sample, streamlining workflows for laboratories and providing rapid results to physicians. For example, gastrointestinal infections commonly present with similar or identical symptoms but can be caused by more than 25 organisms. Highly multiplexed assays allow clinicians to identify which organism is responsible for an infection quickly, accurately and efficiently.

“One of our key goals is to use our strong cash flow to create a larger, faster growing company for a post-pandemic world,” said Steve MacMillan, Hologic’s chairman, president and chief executive officer. “Mobidiag provides an exceptional new growth platform, which will generate long-term value by enabling us to enter the acute care market, which is expected to roughly double in the next five years, with a differentiated, highly competitive solution.”

Mobidiag generated approximately $42 million (€35 million) of revenue in calendar 2020. Hologic intends to invest in assay development to drive growth of the Novodiag platform. As a result, the acquisition is expected to be approximately $0.10 dilutive to Hologic’s non-GAAP earnings per share in fiscal 2022, slightly dilutive in 2023, and accretive thereafter. Hologic expects to finance the transaction with cash on hand and borrowing on its existing line of credit.

The acquisition is expected to close early in the fourth quarter of fiscal 2021, subject to receipt of certain required regulatory approvals and other customary closing conditions.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

Hologic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

About Mobidiag

Mobidiag is a commercial stage, fast-growing Finnish-French biotechnology company that develops and markets innovative molecular diagnostic solutions for gastrointestinal infections, antimicrobial resistance management, healthcare associated infections (HAIs), respiratory infections and sepsis. Based on well-established qPCR and microarray technologies, Mobidiag offers a broad range of tests and automated platforms. These include a comprehensive range of fast, reliable and cost-effective molecular diagnostic solutions for the detection of infectious diseases adapted to laboratories of all sizes. They allow detection of most clinically relevant bacteria, parasites, viruses and markers for antibiotic resistance.

Misconceptions abound about vitiligo, a visible condition that affects the skin. So too do stigma and discrimination. Throughout history, vitiligo has been wrongly associated with leprosy, sexually transmitted infections (STIs), and physical and mental disabilities. Many of these misconceptions are based on little to no understanding about what vitiligo actually is.

Raising awareness and sharing accurate information is one way to help dispel the harmful myths and misunderstandings about vitiligo.

What Is Vitiligo?

Vitiligo is an autoimmune condition that affects 1 to 2 percent of the global population, meaning millions of people live with vitiligo. Vitiligo causes progressive loss of pigmentation in areas of the skin, mucous membranes, and hair. As a result, vitiligo is characterised by patches of white skin or hair. Vitiligo affects people of all races and ethnicities equally, but due to the level of contrast, these lighter patches are generally more noticeable the darker a person’s complexion is.

Myth #1: You Can Catch Vitiligo By Coming in Contact With a Person Who Has It

Vitiligo is not a contagious disease. While scientists aren’t sure of the exact cause, vitiligo is considered to be an autoimmune disease, with a genetic predisposition and environmental factors (like stress) at play in most cases. An autoimmune disease is one in which the body’s immune system mistakenly attacks its own healthy tissues as if they were invading harmful agents such as viruses or bacteria. In the case of vitiligo, the body attacks the melanin in the skin. Melanin gives the skin its color — the less melanin in the skin, the lighter it is.

Myth #2: You Can Cure Vitiligo and Return the Skin Back to Its Original Color

A cure for vitiligo is not yet known, but various vitiligo treatments exist. These include topical medications, oral medications, ultraviolet (UV) therapy, and surgeries such as skin grafts. Existing therapies satisfactorily manage or slow progressions of vitiligo in approximately 75 percent of people affected by the disorder.

Corticosteroids, in particular, can stop the progression of vitiligo in approximately 4 out of 5 people affected by the condition. Systemic corticosteroids are a potent treatment, however, and their use comes with the risk of possible side effects. For this reason, corticosteroids aren’t widely prescribed to every person with vitiligo. Research is ongoing in an effort to find a cure for vitiligo.

Myth #3: If You Have Vitiligo and Have Children, They Will Have Vitiligo

A lot of people ask “Is vitiligo hereditary?” Vitiligo is not solely genetically transmitted, meaning it is not a condition that is inherited from your parents or close family members. Vitiligo is likely caused by a combination of genetic and environmental factors. If vitiligo were purely genetic, identical twins of someone with vitiligo would always also have the condition. However, identical twins both have vitiligo in only 23 percent of cases. That said, up to 20 percent of those living with vitiligo report one or more relatives who also have vitiligo.

Notice how some people have the most dazzling smiles? They almost seem too perfect to be real. The good news is that everyone can acquire that smile for themselves, mostly through lifestyle changes.

The most striking characteristic of a new acquaintance is the smile. According to 48 % of adults in the US, a bright smile is the best way to make an excellent first impression. The survey also revealed that 37% of the respondents would have their crooked or stained teeth fixed if they have the same dental issues.

It’s not a secret that stained teeth are a major source of concern for some—this can lower self-confidence in many ways. If you’re searching for a solution to this problem, you’ll find countless ways to whiten your teeth on the web. It’s not that these tactics don’t work, but they might be harmful.

Despite recent technological advances, it’s important to remember that teeth are never entirely white. Their natural color may vary from time to time, which is healthy and acceptable. The following tips can help you lighten your teeth without undergoing extensive treatment.

1. Hire Dental Professionals

While you can purchase whitening kits from any drug store, it is better to go to a dentist in your locality and get more information about a professional whitening procedure. Only your dentist can provide the tools and techniques needed for a truly stunning smile.

Your dentist will perform a dental evaluation and recommend the best treatment for your teeth. Any type of dental whitening procedure will be done with products using professional-grade bleaching that will break down stains into smaller and less concentrated pieces. This can restore your teeth to their natural whiteness and help you smile more confidently. Laser teeth whitening may also be performed.

2. Maintain Proper Oral Hygiene

Keeping your teeth white and bright begins with good oral health. This includes brushing and flossing twice a day and using mouthwash to get rid of harmful bacteria. You may also learn some ways to maintain oral health and ensure you have the best smile. Keeping your teeth clean after eating can keep them stain-free, and adding whitening toothpaste to your routine can enhance brightness.

3. Consider Porcelain Veneers

In case your smile needs more than simple teeth whitening, veneers offer powerful means of improving your smile. Each porcelain veneer is a fragile, custom-made shell of porcelain designed to cover the front half of your tooth.

Due to porcelain’s translucent quality, it closely mimics the look and feel of your natural teeth. Over the years, porcelain veneers have been established as one of the most popular products for creating natural-looking smiles. They only need minor care to last from 15 to 20 years, thanks to porcelain’s durability.

Patients should expect to receive many veneers at once. Some patients probably only need one veneer to cover their broken or jagged tooth, while others prefer to receive six to eight veneers to improve the quality of their smile and make their teeth look as symmetrical as possible along the top of their teeth.

4. Be Mindful Of What You Consume

Various drinks and food may cause tooth discoloration when consumed regularly. Red wine, caffeinated drinks, sports drinks, soft drinks, and even some fruits are the usual culprits. Chromogens are the molecules in intensely pigmented foods that bind to the enamel of your teeth. Thus, reducing your consumption of these foods can help prevent teeth stains.

Brushing immediately after eating can also help. However, you should avoid brushing your teeth right after consuming acidic foods due to possible enamel damage.

The other important factor in keeping your teeth white is to avoid smoking or quit smoking altogether. Tobacco use can significantly affect your health, including your dental health. Significant tooth discoloration may result from smoking or chewing tobacco.

5. Try Using Activated Charcoal Toothbrush

Activated charcoal is considered a very effective remedy in healing teeth stains, yellowness, and brown streaks. Your teeth are gently cleaned by removing toxins and discoloration-causing molecules.

A charcoal toothbrush is effective in preventing gingivitis and can keep your teeth white and healthy. This is due to the activated charcoal.

These are some of the benefits of a charcoal toothbrush over a conventional one:

• Removing plaque without causing tooth weakness or sensitivity
• By pulling stains from enamel, the toothbrush adds more whitening power
• Detoxifies teeth and gums
• Cleans gum tissues by removing pathogenic organisms

Conclusion

You can never go wrong with a trip to the dentist. In mild cases, activated toothbrushes and some other proven home teeth whitening remedies can address tooth discoloration. However, these remedies won’t be able to remove hard stains. Although store-bought solutions may work, your dentist knows how to whiten teeth without sacrificing their longevity. Thus, taking a trip to the dentist is always the most effective way to brighten up your smile.

Kids usually spend most of their time outside because having fun and playing outdoors are what makes them active. However, being exposed under the sun for a long time may cause skin ailments, especially in humid areas like Florida. This state is mostly surrounded by beaches, so its neighboring cities like Miami and Orlando often have high temperatures.

Children have very sensitive skin that’s more prone to sunburns. If your kid is experiencing skin problems, you may want to consider consulting a dermatologist in Orlando to ensure their safety.

Sunscreen as a Remedy

But besides consulting a medical professional, what parents can also do is apply a sunscreen to their children for additional protection when they’re outdoors. This basic practice would keep them from having burns and rashes.

However, not all sunscreens available on the market are safe to use. Some may work well, while some may unfortunately cause harm. That’s why it’s vital to choose a sunscreen which will be gentle to your child’s skin while keeping them safeguarded from the intense sunrays.

To help you in picking the right one, here are some tips you can follow:

1. Consider the SPF

Choose a sunscreen which has a Sun Protection Factor (SPF) of at least 15-30 SPF. It’s within this range that the product would have a mild effect to the skin. Sunscreens with higher SPFs don’t necessarily guarantee much protection, especially that it has more chemicals involved. Additionally, the ones with higher SPFs lasts the same period as a sunscreen with a low SPF, so the higher number doesn’t mean the better.

A general rule of thumb for sunscreens is to choose products that are relatively low in SPF, so it would provide a lighter feeling for the children.

2. Choose Mineral Sunscreen

Minerals are crucial for kids who have susceptible skin. Several pediatricians in Virginia and in other states in America believe there are two main ingredients considered to be effective and safe for sunscreen use–titanium dioxide and zinc oxide. These ingredients lessen the risk of toxic exposure since they’re sitting on top of the skin to block the rays of the sun instead of absorbing it.

Since researches are still assessing the efficacy and safety of particular chemicals found in sunscreens, it’s recommended that parents avail a product with the mineral components mentioned. See to it that you read the ingredients at the back of the product before purchasing. Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */
table.MsoNormalTable
{mso-style-name:”Table Normal”;
mso-tstyle-rowband-size:0;
mso-tstyle-colband-size:0;
mso-style-noshow:yes;
mso-style-priority:99;
mso-style-parent:””;
mso-padding-alt:0in 5.4pt 0in 5.4pt;
mso-para-margin-top:0in;
mso-para-margin-right:0in;
mso-para-margin-bottom:8.0pt;
mso-para-margin-left:0in;
line-height:107%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:”Calibri”,sans-serif;
mso-ascii-font-family:Calibri;
mso-ascii-theme-font:minor-latin;
mso-hansi-font-family:Calibri;
mso-hansi-theme-font:minor-latin;
mso-bidi-font-family:”Times New Roman”;
mso-bidi-theme-font:minor-bidi;}

3. Avoid Spray Sunscreen

Sprays can pose danger when not used correctly because it can be inhaled by the child. If possible, parents are advised not to spray sunscreens since improper handling of it may harm other parts of the body such as the eyes and mouth.

A lotion sunscreen tends to offer more protection since you can easily gauge how much you’re putting on the skin of your child. Many prefer sunscreen being applied by hand because typically, people are getting lesser out of sprayed products since they’re only using it for a few seconds. Applying by hand makes it stick longer to the skin.

4. Opt for a Water-Resistant Option

If your child is going underwater, it’s best to choose a water-resistant sunscreen. Sunscreen is considered water-resistant if its SPF level stays effective for 40 minutes in the water. A better quality sunscreen is one which can last after an hour of swimming. Since it eventually fades, you’ll need to apply more frequently if your child is taking a dip longer.

5. Choose a Sunscreen with a Broad Spectrum

A sunscreen which can protect your child from UVA as well as UVB rays is called broad-spectrum sunscreen. Both UVA and UVB rays can cause danger to the skin and prematurely age it, so it’s crucial to protect your child against these rays. Overexposure may result in skin cancer and sunburns.

To be sure, check the label of the sunscreen if there’s ‘broad-spectrum’ written.

Final Thoughts

There is no one size fits all when it comes to sunscreens, so make sure to take into account the above-mentioned tips in choosing the best product for kids. Sunscreen isn’t only used for the warm and beach weather since it’s still advantageous to apply regardless of the climate.

Remember that a sunscreen is just one of the many tools to protect the skin of your kids. It’s also important to keep an eye on the overall health condition of your child. Other factors such as using comfortable clothing and letting your child wear hat and sunglasses may considerably lessen their risk of having sunburn as well.

In the US, the world of healthcare coverage can confuse even the smartest or savviest individual. Until we have a single-payer option or universal healthcare, every citizen must do what they can to get coverage to pay for doctor visits, hospital stays, ambulance rides in emergencies, prescription drug coverage, and so forth. It doesn’t seem like government-funded universal healthcare is going to happen anytime soon, though.

Because of that, most individuals must either get healthcare through their work, or else they have to pay for it through the marketplace. If you’re looking at the different healthcare plans available to you, you might see that some are high deductible plans, while others come with low deductibles. We’ll explain the difference between the two right now, and we’ll also talk about some of the benefits and drawbacks of each one.

Do You Really Need Health Insurance?

Even if you have healthcare, and you go see a doctor or spend some time in a hospital, there are certain inherent risks that go along with that. Medical malpractice can occur sometimes, and if it ever does, you might end up in worse physical condition than before you sought treatment.

Still, getting to see a doctor is your best chance if you’re sick or injured, and you need healthcare before some doctors or hospitals will even see you. When you show up at the emergency room, the first thing they’ll ask is what’s wrong with you, but the second question will be what insurance you have.

If you don’t have insurance, then your best chance at medical care is to go to a free clinic. Such facilities often face overcrowding, though, since they have to serve large groups of underprivileged individuals. The simple truth is that there’s nothing you can have that’s more vital than healthcare since, at some point, it’s almost certain that you’ll have to deal with a medical issue.

Your Best Options for Getting Healthcare

As we mentioned before, you might be able to get health insurance when you get a job. In fact, for many people, getting a job because of the health insurance that potentially comes with it is every bit as vital as the salary you’ll earn.

The other way you can get healthcare is through the marketplace. You might do that if you’re a freelancer or you’re self-employed.

State governments help individuals who don’t make very much money. They will partially subsidize your health care purchase. Some states are better about doing that than others, though, and trying to navigate the system is often time-consuming and tricky, if not downright frustrating.

Regardless of whether you purchase healthcare on your own or get it through your job, you will probably see different pricing tiers. They will have different names or levels depending on the company from which you’re buying it. The levels might be bronze, silver, and gold, or some similar system.

The Fundamental Difference Between High and Low Deductible Plans

If you get a low-tier plan, such as the bronze package, that’s probably going to be a high deductible plan. That means you’ll pay a lower price every month. The company calls the monthly fee a premium.

If you get a better plan, you’ll pay a higher premium every month. Better plans are low-deductible plans.

If you get a low deductible plan, then you have to pay more every month, but a doctor’s office or hospital will not charge you as much for the various services you might require. If you get a high deductible plan, then you pay less every month, but you’ll pay more out of pocket if you contract an illness and need emergency treatment.

Which One is Better?

All insurance is gambling, and health insurance is no exception to that. You can’t really say that either a high or low deductible plan is the better option. Getting either one represents a dice roll.

Generally, if you’re younger and healthier, it makes more sense to get a high deductible plan. You’re betting on not getting sick or hurting yourself, so it’s not as likely that you’ll end up in the hospital or require urgent care.

If you’re older and know that you have various medical problems, you should probably pay for the low deductible plan. You’ll have to pay more every month, but when you inevitably have to see more doctors and spend more time in hospitals, you’ll pay less at that time for their services.